Top

Published in:

Open Access 01-01-2011 | Review

The pancreas in human type 1 diabetes

Authors: Patrick A. Rowe, Martha L. Campbell-Thompson, Desmond A. Schatz, Mark A. Atkinson

Published in: Seminars in Immunopathology | Issue 1/2011

Abstract

Type 1 diabetes (T1D) is considered a disorder whose pathogenesis is autoimmune in origin, a notion drawn in large part from studies of human pancreata performed as far back as the 1960s. While studies of the genetics, epidemiology, and peripheral immunity in T1D have been subject to widespread analysis over the ensuing decades, efforts to understand the disorder through analysis of human pancreata have been far more limited. We have reviewed the published literature pertaining to the pathology of the human pancreas throughout all stages in the natural history of T1D. This effort uncovered a series of findings that challenge many dogmas ascribed to T1D and revealed data suggesting the marked heterogeneity in terms of its pathology. An improved understanding and appreciation for pancreatic pathology in T1D could lead to improved disease classification, an understanding of why the disorder occurs, and better therapies for disease prevention and management.

Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2003) Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 290:2159–2167CrossRef

Aizawa T, Kaneko T, Yamauchi K, Yajima H, Nishizawa T, Yada T, Matsukawa H, Nagai M, Yamada S, Sato Y, Komatsu M, Itoh N, Hidaka H, Kajimoto Y, Hashizume K (2001) Size-related and size-unrelated functional heterogeneity among pancreatic islets. Life Sci 69:2627–2639PubMedCrossRef

Akerblom HK, Savilahti E, Saukkonen TT, Paganus A, Virtanen SM, Teramo K, Knip M, Ilonen J, Reijonen H, Karjalainen J et al (1993) The case for elimination of cow's milk in early infancy in the prevention of type 1 diabetes: the Finnish experience. Diab Metab Rev 9:269–278CrossRef

Argoud GM, Schade DS, Eaton RP (1987) Insulin suppresses its own secretion in vivo. Diabetes 36:959–962PubMedCrossRef

Atkinson MA, Maclaren NK, Luchetta R (1990) Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes 39:933–937PubMedCrossRef

Atkinson MA, Kaufman DL, Newman D, Tobin AJ, Maclaren NK (1993) Islet cell cytoplasmic autoantibody reactivity to glutamate decarboxylase in insulin-dependent diabetes. J Clin Invest 91:350–356PubMedCrossRef

Atkinson MA (1997) Molecular mimicry and the pathogenesis of insulin-dependent diabetes mellitus: still just an attractive hypothesis. Ann Med 29:393–399PubMedCrossRef

Atkinson MA, Leiter EH (1999) The NOD mouse model of type 1 diabetes: as good as it gets? Nat Med 5:601–604PubMedCrossRef

Atkinson MA, Gianani R (2009) The pancreas in human type 1 diabetes: providing new answers to age-old questions. Curr Opin Endocrinol Diab Obes 16:279–285CrossRef

10.

Bjork E, Berne C, Kampe O, Wibell L, Oskarsson P, Karlsson FA (1996) Diazoxide treatment at onset preserves residual insulin secretion in adults with autoimmune diabetes. Diabetes 45:1427–1430PubMedCrossRef

11.

Borchers AT, Uibo R, Gershwin ME (2010) The geoepidemiology of type 1 diabetes. Autoimmun Rev 9:A355–A365PubMedCrossRef

12.

Bottazzo GF, Dean BM, McNally JM, MacKay EH, Swift PG, Gamble DR (1985) In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N Engl J Med 313:353–360PubMedCrossRef

13.

Bowman MA, Campbell L, Darrow BL, Ellis TM, Suresh A, Atkinson MA (1996) Immunological and metabolic effects of prophylactic insulin therapy in the NOD-scid/scid adoptive transfer model of IDDM. Diabetes 45:205–208PubMedCrossRef

14.

Brown RJ, Rother KI (2008) Effects of beta-cell rest on beta-cell function: a review of clinical and preclinical data. Pediatr Diab 9:14–22CrossRef

15.

Brugman S, Klatter FA, Visser JT, Wildeboer-Veloo AC, Harmsen HJ, Rozing J, Bos NA (2006) Antibiotic treatment partially protects against type 1 diabetes in the Bio-Breeding diabetes-prone rat. Is the gut flora involved in the development of type 1 diabetes? Diabetologia 49:2105–2108PubMedCrossRef

16.

Buschard K, Brogren CH, Ropke C, Rygaard J (1988) Antigen expression of the pancreatic beta-cells is dependent on their functional state, as shown by a specific, BB rat monoclonal autoantibody IC2. APMIS 96:342–346PubMedCrossRef

17.

Butler AE, Galasso R, Meier JJ, Basu R, Rizza RA, Butler PC (2007) Modestly increased beta cell apoptosis but no increased beta cell replication in recent-onset type 1 diabetic patients who died of diabetic ketoacidosis. Diabetologia 50:2323–2331PubMedCrossRef

18.

Dahlquist G (2006) Can we slow the rising incidence of childhood-onset autoimmune diabetes? The overload hypothesis. Diabetologia 49:20–24PubMedCrossRef

19.

Fan Y, Rudert WA, Grupillo M, He J, Sisino G, Trucco M (2009) Thymus-specific deletion of insulin induces autoimmune diabetes. EMBO J 28:2812–2824PubMedCrossRef

20.

Ferrannini E, Mari A, Nofrate V, Sosenko JM, Skyler JS (2010) Progression to diabetes in relatives of type 1 diabetic patients: mechanisms and mode of onset. Diabetes 59:679–685PubMedCrossRef

21.

Foulis AK, Stewart JA (1984) The pancreas in recent-onset type 1 (insulin-dependent) diabetes mellitus: insulin content of islets, insulitis and associated changes in the exocrine acinar tissue. Diabetologia 26:456–461PubMedCrossRef

22.

Foulis AK, Liddle CN, Farquharson MA, Richmond JA, Weir RS (1986) The histopathology of the pancreas in type 1 (insulin-dependent) diabetes mellitus: a 25-year review of deaths in patients under 20 years of age in the United Kingdom. Diabetologia 29:267–274PubMedCrossRef

23.

Foulis AK (1996) The pathology of the endocrine pancreas in type 1 (insulin-dependent) diabetes mellitus. APMIS 104:161–167PubMedCrossRef

24.

Fourlanos S, Varney MD, Tait BD, Morahan G, Honeyman MC, Colman PG, Harrison LC (2008) The rising incidence of type 1 diabetes is accounted for by cases with lower-risk human leukocyte antigen genotypes. Diab Care 31:1546–1549CrossRef

25.

Fousteri G, von Herrath M, Bresson D (2007) Mucosal exposure to antigen: cause or cure of type 1 diabetes? Curr Diab Rep 7:91–98PubMedCrossRef

26.

Fox CS, Coady S, Sorlie PD, D'Agostino RB Sr, Pencina MJ, Vasan RS, Meigs JB, Levy D, Savage PJ (2007) Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 115:1544–1550PubMedCrossRef

27.

Fronczak CM, Baron AE, Chase HP, Ross C, Brady HL, Hoffman M, Eisenbarth GS, Rewers M, Norris JM (2003) In utero dietary exposures and risk of islet autoimmunity in children. Diab Care 26:3237–3242CrossRef

28.

Gepts W (1965) Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 14:619–633PubMed

29.

Gepts W, De Mey J (1978) Islet cell survival determined by morphology. An immunocytochemical study of the islets of Langerhans in juvenile diabetes mellitus. Diabetes 27(Suppl 1):251–261PubMed

30.

Gersell DJ, Gingerich RL, Greider MH (1979) Regional distribution and concentration of pancreatic polypeptide in the human and canine pancreas. Diabetes 28:11–15PubMedCrossRef

31.

Gianani R, Putnam A, Still T, Yu L, Miao D, Gill RG, Beilke J, Supon P, Valentine A, Iveson A, Dunn S, Eisenbarth GS, Hutton J, Gottlieb P, Wiseman A (2006) Initial results of screening of nondiabetic organ donors for expression of islet autoantibodies. J Clin Endocrinol Metab 91:1855–1861PubMedCrossRef

32.

Gianani R, Campbell-Thompson M, Sarkar SA, Wasserfall C, Pugliese A, Solis JM, Kent SC, Hering BJ, West E, Steck A, Bonner-Weir S, Atkinson MA, Coppieters K, von Herrath M, Eisenbarth GS (2010) Dimorphic histopathology of long-standing childhood-onset diabetes. Diabetologia 53:690–698PubMedCrossRef

33.

Hagopian WA, Karlsen AE, Petersen JS, Teague J, Gervassi A, Jiang J, Fujimoto W, Lernmark A (1993) Regulation of glutamic acid decarboxylase diabetes autoantigen expression in highly purified isolated islets from Macaca nemestrina. Endocrinology 132:2674–2681PubMedCrossRef

34.

Hanafusa T, Imagawa A (2008) Insulitis in human type 1 diabetes. Ann N Y Acad Sci 1150:297–299PubMedCrossRef

35.

Hasel C, Bhanot UK, Heydrich R, Strater J, Moller P (2005) Parenchymal regression in chronic pancreatitis spares islets reprogrammed for the expression of NFkappaB and IAPs. Lab Invest 85:1263–1275PubMedCrossRef

36.

Hayek A, Woodside W (1979) Correlation between morphology and function in isolated islets of the Zucker rat. Diabetes 28:565–569PubMedCrossRef

37.

Huang Y, Parker M, Xia C, Peng R, Wasserfall C, Clarke T, Wu L, Chowdhry T, Campbell-Thompson M, Williams J, Clare-Salzler M, Atkinson MA, Womer KL (2009) Rabbit polyclonal mouse antithymocyte globulin administration alters dendritic cell profile and function in NOD mice to suppress diabetogenic responses. J Immunol 182:4608–4615PubMedCrossRef

38.

Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y (2000) A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group. N Engl J Med 342:301–307PubMedCrossRef

39.

Imagawa A, Hanafusa T, Makino H, Miyagawa JI, Juto P (2005) High titres of IgA antibodies to enterovirus in fulminant type-1 diabetes. Diabetologia 48:290–293PubMedCrossRef

40.

In't Veld P, Lievens D, De Grijse J, Ling Z, Van der Auwera B, Pipeleers-Marichal M, Gorus F, Pipeleers D (2007) Screening for insulitis in adult autoantibody-positive organ donors. Diabetes 56:2400–2404PubMedCrossRef

41.

Itoh N, Hanafusa T, Miyazaki A, Miyagawa J, Yamagata K, Yamamoto K, Waguri M, Imagawa A, Tamura S, Inada M et al (1993) Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J Clin Invest 92:2313–2322PubMedCrossRef

42.

Ize-Ludlow D, Sperling MA (2005) The classification of diabetes mellitus: a conceptual framework. Pediatr Clin N Am 52:1533–1552CrossRef

43.

Jansen A, Homo-Delarche F, Hooijkaas H, Leenen PJ, Dardenne M, Drexhage HA (1994) Immunohistochemical characterization of monocytes-macrophages and dendritic cells involved in the initiation of the insulitis and beta-cell destruction in NOD mice. Diabetes 43:667–675PubMedCrossRef

44.

Jansen A, Rosmalen JG, Homo-Delarche F, Dardenne M, Drexhage HA (1996) Effect of prophylactic insulin treatment on the number of ER-MP23+ macrophages in the pancreas of NOD mice. Is the prevention of diabetes based on beta-cell rest? J Autoimmun 9:341–348PubMedCrossRef

45.

Julier C, Akolkar B, Concannon P, Morahan G, Nierras C, Pugliese A (2009) The Type I Diabetes Genetics Consortium ‘Rapid Response’ family-based candidate gene study: strategy, genes selection, and main outcome. Genes Immun 10(Suppl 1):S121–S127PubMedCrossRef

46.

Junker K, Egeberg J, Kromann H, Nerup J (1977) An autopsy study of the islets of Langerhans in acute-onset juvenile diabetes mellitus. Acta Pathol Microbiol Scand A 85:699–706PubMed

47.

Kaufman DL, Clare-Salzler M, Tian J, Forsthuber T, Ting GS, Robinson P, Atkinson MA, Sercarz EE, Tobin AJ, Lehmann PV (1993) Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 366:69–72PubMedCrossRef

48.

Kida K, Mimura G, Kobayashi T, Matsuura N, Toyota T, Kitagawa T, Hibi I, Ikeda Y, Tuchida I, Kuzuya H et al (1994) ICA and organ-specific autoantibodies among Japanese patients with early-onset insulin-dependent diabetes mellitus—the JDS study. Diab Res Clin Pract 23:187–193CrossRef

49.

Klinke DJ 2nd (2008) Extent of beta cell destruction is important but insufficient to predict the onset of type 1 diabetes mellitus. PLoS ONE 3:e1374PubMedCrossRef

50.

Korhonen S, Knip MM, Kulmala P, Savola K, Akerblom HK, Knip M (2002) Autoantibodies to GAD, IA-2 and insulin in ICA-positive first-degree relatives of children with type 1 diabetes: a comparison between parents and siblings. Diabetes Metab Res Rev 18:43–48PubMedCrossRef

51.

Lee CH, Chen YG, Chen J, Reifsnyder PC, Serreze DV, Clare-Salzler M, Rodriguez M, Wasserfall C, Atkinson MA, Leiter EH (2006) Novel leptin receptor mutation in NOD/LtJ mice suppresses type 1 diabetes progression: II. Immunologic analysis. Diabetes 55:171–178PubMedCrossRef

52.

Lee YS, Ng WY, Thai AC, Lui KF, Loke KY (2001) Prevalence of ICA and GAD antibodies at initial presentation of type 1 diabetes mellitus in Singapore children. J Pediatr Endocrinol Metab 14:767–772PubMedCrossRef

53.

Lehmann R, Zuellig RA, Kugelmeier P, Baenninger PB, Moritz W, Perren A, Clavien PA, Weber M, Spinas GA (2007) Superiority of small islets in human islet transplantation. Diabetes 56:594–603PubMedCrossRef

54.

Leiter EH, Prochazka M, Coleman DL (1987) The non-obese diabetic (NOD) mouse. Am J Pathol 128:380–383PubMed

55.

Lempainen J, Vaarala O, Makela M, Veijola R, Simell O, Knip M, Hermann R, Ilonen J (2009) Interplay between PTPN22 C1858T polymorphism and cow's milk formula exposure in type 1 diabetes. J Autoimmun 33:155–164PubMedCrossRef

56.

Liggins C, Orlicky DJ, Bloomquist LA, Gianani R (2003) Developmentally regulated expression of Survivin in human pancreatic islets. Pediatr Dev Pathol 6:392–397PubMedCrossRef

57.

Luopajarvi K, Savilahti E, Virtanen SM, Ilonen J, Knip M, Akerblom HK, Vaarala O (2008) Enhanced levels of cow's milk antibodies in infancy in children who develop type 1 diabetes later in childhood. Pediatr Diab 9:434–441CrossRef

58.

MacDonald PE, Joseph JW, Yau D, Diao J, Asghar Z, Dai F, Oudit GY, Patel MM, Backx PH, Wheeler MB (2004) Impaired glucose-stimulated insulin secretion, enhanced intraperitoneal insulin tolerance, and increased beta-cell mass in mice lacking the p110gamma isoform of phosphoinositide 3-kinase. Endocrinology 145:4078–4083PubMedCrossRef

59.

MacFarlane AJ, Strom A, Scott FW (2009) Epigenetics: deciphering how environmental factors may modify autoimmune type 1 diabetes. Mamm Genome 20:624–632PubMedCrossRef

60.

MacGregor RR, Williams SJ, Tong PY, Kover K, Moore WV, Stehno-Bittel L (2006) Small rat islets are superior to large islets in in vitro function and in transplantation outcomes. Am J Physiol Endocrinol Metab 290:E771–E779PubMedCrossRef

61.

Maclaren N, Lan M, Coutant R, Schatz D, Silverstein J, Muir A, Clare-Salzer M, She JX, Malone J, Crockett S, Schwartz S, Quattrin T, DeSilva M, Vander Vegt P, Notkins A, Krischer J (1999) Only multiple autoantibodies to islet cells (ICA), insulin, GAD65, IA-2 and IA-2beta predict immune-mediated (Type 1) diabetes in relatives. J Autoimmun 12:279–287PubMedCrossRef

62.

Makino S, Kunimoto K, Muraoka Y, Mizushima Y, Katagiri K, Tochino Y (1980) Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu 29:1–13PubMed

63.

Martin CL, Albers J, Herman WH, Cleary P, Waberski B, Greene DA, Stevens MJ, Feldman EL (2006) Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diab Care 29:340–344CrossRef

64.

McEvoy RC, Madson KL (1980) Pancreatic insulin-, glucagon-, and somatostatin-positive islet cell populations during the perinatal development of the rat. II. Changes in hormone content and concentration. Biol Neonate 38:255–259PubMedCrossRef

65.

Mehers KL, Gillespie KM (2008) The genetic basis for type 1 diabetes. Br Med Bull 88:115–129PubMedCrossRef

66.

Meier JJ, Butler AE, Saisho Y, Monchamp T, Galasso R, Bhushan A, Rizza RA, Butler PC (2008) Beta-cell replication is the primary mechanism subserving the postnatal expansion of beta-cell mass in humans. Diabetes 57:1584–1594PubMedCrossRef

67.

Muntoni S (2006) Epidemiological association between some dietary habits and the increasing incidence of type 1 diabetes worldwide. Ann Nutr Metab 50:11–19PubMedCrossRef

68.

Neu A, Ehehalt S, Willasch A, Kehrer M, Hub R, Ranke MB (2001) Rising incidence of type 1 diabetes in Germany: 12-year trend analysis in children 0–14 years of age. Diab Care 24:785–786CrossRef

69.

Ortqvist E, Bjork E, Wallensteen M, Ludvigsson J, Aman J, Johansson C, Forsander G, Lindgren F, Berglund L, Bengtsson M, Berne C, Persson B, Karlsson FA (2004) Temporary preservation of beta-cell function by diazoxide treatment in childhood type 1 diabetes. Diab Care 27:2191–2197CrossRef

70.

Ouyang Q, Standifer NE, Qin H, Gottlieb P, Verchere CB, Nepom GT, Tan R, Panagiotopoulos C (2006) Recognition of HLA class I-restricted beta-cell epitopes in type 1 diabetes. Diabetes 55:3068–3074PubMedCrossRef

71.

Parker MJ, Xue S, Alexander JJ, Wasserfall CH, Campbell-Thompson ML, Battaglia M, Gregori S, Mathews CE, Song S, Troutt M, Eisenbeis S, Williams J, Schatz DA, Haller MJ, Atkinson MA (2009) Immune depletion with cellular mobilization imparts immunoregulation and reverses autoimmune diabetes in nonobese diabetic mice. Diabetes 58:2277–2284PubMedCrossRef

72.

Pelegri C, Rosmalen JG, Durant S, Throsby M, Alves V, Coulaud J, Esling A, Pleau JM, Drexhage HA, Homo-Delarche F (2001) Islet endocrine-cell behavior from birth onward in mice with the nonobese diabetic genetic background. Mol Med 7:311–319PubMed

73.

Pundziute-Lycka A, Persson LA, Cedermark G, Jansson-Roth A, Nilsson U, Westin V, Dahlquist G (2004) Diet, growth, and the risk for type 1 diabetes in childhood: a matched case-referent study. Diab Care 27:2784–2789CrossRef

74.

Rangasami JJ, Greenwood DC, McSporran B, Smail PJ, Patterson CC, Waugh NR (1997) Rising incidence of type 1 diabetes in Scottish children, 1984–93. The Scottish Study Group for the Care of Young Diabetics. Arch Dis Child 77:210–213PubMedCrossRef

75.

Rasmussen SB, Sorensen TS, Hansen JB, Mandrup-Poulsen T, Hornum L, Markholst H (2000) Functional rest through intensive treatment with insulin and potassium channel openers preserves residual beta-cell function and mass in acutely diabetic BB rats. Horm Metab Res 32:294–300PubMedCrossRef

76.

Rodriguez-Villar C, Conget I, Casamitjana R, Ercilla G, Gomis R (1999) Effects of insulin administration in a group of high-risk, non-diabetic, first-degree relatives of Type 1 diabetic patients: an open pilot trial. Diabet Med 16:160–163PubMedCrossRef

77.

Roep BO, Hiemstra HS, Schloot NC, De Vries RR, Chaudhuri A, Behan PO, Drijfhout JW (2002) Molecular mimicry in type 1 diabetes: immune cross-reactivity between islet autoantigen and human cytomegalovirus but not Coxsackie virus. Ann N Y Acad Sci 958:163–165PubMedCrossRef

78.

Rosmalen JG, Homo-Delarche F, Durant S, Kap M, Leenen PJ, Drexhage HA (2000) Islet abnormalities associated with an early influx of dendritic cells and macrophages in NOD and NODscid mice. Lab Invest 80:769–777PubMedCrossRef

79.

Sakaguchi Y, Inaba M, Kusafuka K, Okazaki K, Ikehara S (2006) Establishment of animal models for three types of pancreatitis and analyses of regeneration mechanisms. Pancreas 33:371–381PubMedCrossRef

80.

Samuelsson U, Ludvigsson J (2004) The concentrations of short-chain fatty acids and other microflora-associated characteristics in faeces from children with newly diagnosed Type 1 diabetes and control children and their family members. Diabet Med 21:64–67PubMedCrossRef

81.

Savage MO, Smith CP, Dunger DB, Gale EA, Holly JM, Preece MA (1992) Insulin and growth factors adaptation to normal puberty. Horm Res 37(Suppl 3):70–73PubMedCrossRef

82.

Shaltout AA, Moussa MA, Qabazard M, Abdella N, Karvonen M, Al-Khawari M, Al-Arouj M, Al-Nakhi A, Tuomilehto J, El-Gammal A (2002) Further evidence for the rising incidence of childhood Type 1 diabetes in Kuwait. Diabet Med 19:522–525PubMedCrossRef

83.

Siljander HT, Simell S, Hekkala A, Lahde J, Simell T, Vahasalo P, Veijola R, Ilonen J, Simell O, Knip M (2009) Predictive characteristics of diabetes-associated autoantibodies among children with HLA-conferred disease susceptibility in the general population. Diabetes 58:2835–2842PubMedCrossRef

84.

Simon G, Parker M, Ramiya V, Wasserfall C, Huang Y, Bresson D, Schwartz RF, Campbell-Thompson M, Tenace L, Brusko T, Xue S, Scaria A, Lukason M, Eisenbeis S, Williams J, Clare-Salzler M, Schatz D, Kaplan B, Von Herrath M, Womer K, Atkinson MA (2008) Murine antithymocyte globulin therapy alters disease progression in NOD mice by a time-dependent induction of immunoregulation. Diabetes 57:405–414PubMedCrossRef

85.

Skak K, Gotfredsen CF, Lundsgaard D, Hansen JB, Sturis J, Markholst H (2004) Improved beta-cell survival and reduced insulitis in a type 1 diabetic rat model after treatment with a beta-cell-selective K(ATP) channel opener. Diabetes 53:1089–1095PubMedCrossRef

86.

Sobel-Maruniak A, Grzywa M, Orlowska-Florek R, Staniszewski A (2006) The rising incidence of type 1 diabetes in south-eastern Poland. A study of the 0–29 year-old age group, 1980–1999. Endokrynol Pol 57:127–130PubMed

87.

Solimena M, Dirkx R Jr, Hermel JM, Pleasic-Williams S, Shapiro JA, Caron L, Rabin DU (1996) ICA 512, an autoantigen of type I diabetes, is an intrinsic membrane protein of neurosecretory granules. EMBO J 15:2102–2114PubMed

88.

Suarez-Pinzon WL, Lakey JR, Brand SJ, Rabinovitch A (2005) Combination therapy with epidermal growth factor and gastrin induces neogenesis of human islet {beta}-cells from pancreatic duct cells and an increase in functional {beta}-cell mass. J Clin Endocrinol Metab 90:3401–3409PubMedCrossRef

89.

Taplin CE, Craig ME, Lloyd M, Taylor C, Crock P, Silink M, Howard NJ (2005) The rising incidence of childhood type 1 diabetes in New South Wales, 1990–2002. Med J Aust 183:243–246PubMed

90.

Toumba M, Savva SC, Bacopoulou I, Apsiotou T, Georgiou T, Stavrou S, Skordis N (2007) Rising incidence of type 1 diabetes mellitus in children and adolescents in Cyprus in 2000–2004. Pediatr Diab 8:374–376CrossRef

91.

Von Meyenburg H (1940) Über ‘insulitis’ bei diabetes. Schweiz Med Wochenschr 21:554

92.

Vreugdenhil GR, Geluk A, Ottenhoff TH, Melchers WJ, Roep BO, Galama JM (1998) Molecular mimicry in diabetes mellitus: the homologous domain in coxsackie B virus protein 2C and islet autoantigen GAD65 is highly conserved in the coxsackie B-like enteroviruses and binds to the diabetes associated HLA-DR3 molecule. Diabetologia 41:40–46PubMedCrossRef

93.

Wagner R, McNally JM, Bonifacio E, Genovese S, Foulis A, McGill M, Christie MR, Betterle C, Bosi E, Bottazzo GF (1994) Lack of immunohistological changes in the islets of nondiabetic, autoimmune, polyendocrine patients with beta-selective GAD-specific islet cell antibodies. Diabetes 43:851–856PubMedCrossRef

94.

Weichselbaum A (1910) Über der Veränderungen des Pankreas bei Diabetes Mellitus. Sitzungsberichte der Kaiserlichen Akademie der Wissenschaften 119:73–281

95.

Weir GC, Bonner-Weir S (2004) Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 53(Suppl 3):S16–S21PubMedCrossRef

96.

Willcox A, Richardson SJ, Bone AJ, Foulis AK, Morgan NG (2009) Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol 155:173–181PubMedCrossRef

97.

Xue S, Wasserfall CH, Parker M, Brusko TM, McGrail S, McGrail K, Moore M, Campbell-Thompson M, Schatz DA, Atkinson MA, Haller MJ (2008) Exendin-4 therapy in NOD mice with new-onset diabetes increases regulatory T cell frequency. Ann N Y Acad Sci 1150:152–156PubMedCrossRef

98.

Xue S, Wasserfall C, Parker M, McGrail S, McGrail K, Campbell-Thompson M, Schatz DA, Atkinson MA, Haller MJ (2009) Exendin-4 treatment of nonobese diabetic mice increases beta-cell proliferation and fractional insulin reactive area. J Diabetes Complications

99.

Yip L, Su L, Sheng D, Chang P, Atkinson M, Czesak M, Albert PR, Collier AR, Turley SJ, Fathman CG, Creusot RJ (2009) Deaf1 isoforms control the expression of genes encoding peripheral tissue antigens in the pancreatic lymph nodes during type 1 diabetes. Nat Immunol 10:1026–1033PubMedCrossRef

100.

Ziegler AG, Baumgartl HJ, Standl E, Mehnert H (1990) Risk of progression to diabetes of low titer ICA-positive first-degree relatives of type I diabetics in southern Germany. J Autoimmun 3:619–624PubMedCrossRef

Title: The pancreas in human type 1 diabetes
Authors: Patrick A. Rowe
Martha L. Campbell-Thompson
Desmond A. Schatz
Mark A. Atkinson
Publication date: 01-01-2011
Publisher: Springer-Verlag
Published in: Seminars in Immunopathology / Issue 1/2011
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-010-0208-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

Innate immunity and the pathogenesis of type 1 diabetes

Immunopathology of the human pancreas in type-I diabetes

Enteroviruses in the pathogenesis of type 1 diabetes

Beta cell regeneration in human pancreas

Beta cells under attack: toward a better understanding of type 1 diabetes immunopathology

Mouse models for the study of autoimmune type 1 diabetes: a NOD to similarities and differences to human disease

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials